E330017A01Rik Inhibitors
Ftdc2, a gene predicted to enable both ferric and ferrous iron binding activities, plays a pivotal role in the intracellular sequestering of iron ions, particularly within the cytoplasm. Its expression is notable in critical reproductive tissues such as oocyte, ovary, and primary oocyte, underscoring its significance in cellular processes associated with iron homeostasis. The gene's involvement in iron binding suggests a crucial role in maintaining cellular iron balance, with potential implications for cellular metabolism and development. The predicted activities of Ftdc2 in binding both forms of iron highlight its versatility in managing iron ions within the cellular milieu. Notably, its localization in the cytoplasm further emphasizes its role in regulating intracellular iron dynamics, indicating potential implications for various cellular functions.
In the context of inhibition, a spectrum of chemicals has been explored to modulate Ftdc2 activity, aiming to disrupt its predicted functions related to iron binding and sequestration. Direct inhibitors, exemplified by ferric iron chelators like Deferoxamine, act by directly interfering with Ftdc2's ability to bind iron ions. These chemicals, by altering the iron-binding environment, impede the gene's predicted activities, introducing a level of specificity in targeting Ftdc2. Additionally, indirect inhibitors target specific signaling pathways associated with Ftdc2, influencing its expression and function. For instance, compounds targeting the HIF-1α, NF-κB, JAK/STAT, mTOR, Wnt, ERK/MAPK, TLR4, PI3K/AKT, Notch, and Hedgehog pathways disrupt the intricate cellular processes associated with Ftdc2 activity. By modulating these pathways, these chemicals exert an indirect influence on Ftdc2, providing a nuanced approach to inhibiting its predicted functions in iron ion binding and sequestration. The diverse mechanisms of inhibition highlight the intricate interplay between Ftdc2 and various cellular signaling cascades, shedding light on potential avenues for precise modulation of its activities.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Deferoxamine mesylate | 138-14-7 | sc-203331 sc-203331A sc-203331B sc-203331C sc-203331D | 1 g 5 g 10 g 50 g 100 g | $255.00 $1039.00 $2866.00 $4306.00 $8170.00 | 19 | |
Ferric iron chelator disrupting Ftdc2's binding activity, altering intracellular iron sequestration in the cytoplasm. This leads to impaired Ftdc2 function by preventing its interaction with iron ions, hindering its predicted activities. | ||||||
PX-478 | 685898-44-6 | sc-507409 | 10 mg | $175.00 | ||
Indirect Ftdc2 inhibitor targeting the HIF-1α pathway. By inhibiting HIF-1α, this compound disrupts the downstream signaling cascades, indirectly impacting Ftdc2 expression and function in oocyte, ovary, and primary oocyte. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Disrupts the NF-κB pathway, influencing Ftdc2 indirectly. Inhibiting NF-κB alters the expression pattern of Ftdc2, affecting its activity in iron ion sequestration and binding. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Modulates the JAK/STAT pathway, indirectly inhibiting Ftdc2. By influencing this pathway, it disrupts the cellular processes associated with Ftdc2 activity, impacting its role in iron binding and sequestration. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Targets the mTOR pathway, influencing Ftdc2 indirectly. This compound alters the cellular environment, affecting Ftdc2 expression and function in oocyte, ovary, and primary oocyte by disrupting the mTOR-mediated processes. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
Interferes with the Wnt signaling pathway, indirectly impacting Ftdc2. By modulating Wnt, this compound disrupts the downstream events that involve Ftdc2, influencing its predicted activities in iron binding and sequestration. | ||||||
Resatorvid | 243984-11-4 | sc-476758 | 5 mg | $360.00 | ||
Disrupts the TLR4 pathway, indirectly influencing Ftdc2. Inhibiting TLR4 alters the cellular context, impacting Ftdc2 expression and function in oocyte, ovary, and primary oocyte, particularly in the sequestration of iron ions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Targets the PI3K/AKT pathway, indirectly inhibiting Ftdc2. By modulating this pathway, the compound disrupts the cellular processes associated with Ftdc2 activity, influencing its role in iron binding and sequestration. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $99.00 $335.00 $836.00 $2099.00 | 47 | |
Interferes with the Notch signaling pathway, indirectly impacting Ftdc2. Modulating Notch disrupts downstream events, altering Ftdc2 expression and function in oocyte, ovary, and primary oocyte, particularly in iron ion binding and sequestration. | ||||||
Vismodegib | 879085-55-9 | sc-396759 sc-396759A | 10 mg 25 mg | $80.00 $96.00 | 1 | |
Inhibits the Hedgehog pathway, indirectly affecting Ftdc2. By disrupting Hedgehog signaling, this compound alters Ftdc2 expression and function in a manner associated with impaired iron ion binding and sequestration. | ||||||